1. Home
  2. Live Updates
  3. மருந்துகள் இல்லாமல்

மருந்துகள் இல்லாமல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மருந்துகள் இல்லாமல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மருந்துகள் இல்லாமல் Today - Breaking & Trending Today

¿Fármacos sin prescripción? Aquí las 4 razones por las que no deberías automedicarte


¿Qué tan conveniente es automedicarse? Si bien se trata de una práctica común entre la población, el tomar fármacos sin receta puede traer, e incluso enmascarar, problemas de salud. Una experta explica a detalle los riesgos de la automedicación y qué hacer cuando hay una enfermedad previo a la ingesta de fármacos sin prescripción.
Madrid, 25 de julio (Europa Press).- La
automedicación es la utilización indiscriminada de medicamentos para patologías o síntomas conocidos entre la población, como gripe o resfriados, dolores por ejemplo, y sin prescripción de ningún profesional, y sin saber, si dichos ....

Christopher Carlson , Mark Lennihan , Toby Talbot , Society Spaniard , Threat To Our Health This , With Europe , Have Been , Pdb With , Pdb For , Doctor Francisca , Drugs Without , Threat To Our Health This Medical , கிறிஸ்டோபர் கார்ல்சன் , டோபி டால்போட் , உடன் யூரோப் , வேண்டும் இருந்தது , மருந்துகள் இல்லாமல் ,

Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic ...


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic .
Algernon PharmaceuticalsFebruary 1, 2021 GMT
VANCOUVER, British Columbia, Feb. 01, 2021 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has established a clinical research program for the treatment of stroke focused on AP-188 (“N,N-Dimethyltryptamine or DMT”), a known psychedelic compound that is part of the tryptamine family (other drugs in the tryptamine family include psilocybin and psilocin). Algernon plans to be the first company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible in 2021. ....

United States , United Kingdom , British Columbia , South Korea , City Of , Christopherj Moreau , Edmundj Safra , Rick Strassman , Neurosciences At Merck Research Labs , Maastricht University , Neurosciences Institute , Clinical Development Solutions , American Association For The Advancement Of Science , Korea Institute Of Science , Nervous System Drugs Advisory Committee , Company Or Algernon , Department Of Medicine , Health Sciences , Head Of The Centre For Neuropsychopharmacology , Winter Conference For Brain Research , Algernon Pharmaceuticals , Constraint Induced Movement Therapy , Brain Science Institute , Scientific Committee On Drugs , European Brain Council , European College Of Neuropsychopharmacology ,